These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12604050)

  • 1. Virosomes in vaccine development: induction of cytotoxic T lymphocyte activity with virosome-encapsulated protein antigens.
    Bungener L; Idema J; ter Veer W; Huckriede A; Daemen T; Wilschut J
    J Liposome Res; 2002; 12(1-2):155-63. PubMed ID: 12604050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.
    Bungener L; Huckriede A; de Mare A; de Vries-Idema J; Wilschut J; Daemen T
    Vaccine; 2005 Jan; 23(10):1232-41. PubMed ID: 15652665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The virosome concept for influenza vaccines.
    Huckriede A; Bungener L; Stegmann T; Daemen T; Medema J; Palache AM; Wilschut J
    Vaccine; 2005 Jul; 23 Suppl 1():S26-38. PubMed ID: 16026906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza vaccines: the virosome concept.
    Wilschut J
    Immunol Lett; 2009 Feb; 122(2):118-21. PubMed ID: 19100779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes.
    Arkema A; Huckriede A; Schoen P; Wilschut J; Daemen T
    Vaccine; 2000 Jan; 18(14):1327-33. PubMed ID: 10618529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs.
    Bungener L; Huckriede A; Wilschut J; Daemen T
    Biosci Rep; 2002 Apr; 22(2):323-38. PubMed ID: 12428908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease.
    Bungener L; de Mare A; de Vries-Idema J; Sehr P; van der Zee A; Wilschut J; Daemen T
    Antivir Ther; 2006; 11(6):717-27. PubMed ID: 17310816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular cytoplasmic delivery of a polypeptide toxin by reconstituted influenza virus envelopes (virosomes).
    Bron R; Ortiz A; Wilschut J
    Biochemistry; 1994 Aug; 33(31):9110-7. PubMed ID: 8049214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells.
    Amacker M; Engler O; Kammer AR; Vadrucci S; Oberholzer D; Cerny A; Zurbriggen R
    Int Immunol; 2005 Jun; 17(6):695-704. PubMed ID: 15843436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virosomes for antigen and DNA delivery.
    Daemen T; de Mare A; Bungener L; de Jonge J; Huckriede A; Wilschut J
    Adv Drug Deliv Rev; 2005 Jan; 57(3):451-63. PubMed ID: 15560951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virosome-mediated delivery of protein antigens to dendritic cells.
    Bungener L; Serre K; Bijl L; Leserman L; Wilschut J; Daemen T; Machy P
    Vaccine; 2002 May; 20(17-18):2287-95. PubMed ID: 12009284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells.
    Angel J; Chaperot L; Molens JP; Mezin P; Amacker M; Zurbriggen R; Grichine A; Plumas J
    Vaccine; 2007 May; 25(19):3913-21. PubMed ID: 17336432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus.
    Hunziker IP; Grabscheid B; Zurbriggen R; Glück R; Pichler WJ; Cerny A
    Int Immunol; 2002 Jun; 14(6):615-26. PubMed ID: 12039913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza virosomes in vaccine development.
    Huckriede A; Bungener L; Daemen T; Wilschut J
    Methods Enzymol; 2003; 373():74-91. PubMed ID: 14714397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monophosphoryl Lipid A-Adjuvanted Virosomes with Ni-Chelating Lipids for Attachment of Conserved Viral Proteins as Cross-Protective Influenza Vaccine.
    Dong W; Bhide Y; Marsman S; Holtrop M; Meijerhof T; de Vries-Idema J; de Haan A; Huckriede A
    Biotechnol J; 2018 Apr; 13(4):e1700645. PubMed ID: 29278302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular delivery of siRNA mediated by fusion-active virosomes.
    Huckriede A; De Jonge J; Holtrop M; Wilschut J
    J Liposome Res; 2007; 17(1):39-47. PubMed ID: 17454402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs.
    de Jonge J; Holtrop M; Wilschut J; Huckriede A
    Gene Ther; 2006 Mar; 13(5):400-11. PubMed ID: 16267567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconstituted Sendai virus envelopes as biological carriers: dual role of F protein in binding and fusion with liver cells.
    Bagai S; Sarkar DP
    Biochim Biophys Acta; 1993 Oct; 1152(1):15-25. PubMed ID: 8399293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro.
    Schumacher R; Amacker M; Neuhaus D; Rosenthal R; Groeper C; Heberer M; Spagnoli GC; Zurbriggen R; Adamina M
    Vaccine; 2005 Dec; 23(48-49):5572-82. PubMed ID: 16165256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of pre-existing immunity on the capacity of influenza virosomes to induce cytotoxic T lymphocyte activity.
    de Mare A; Bungener LB; Regts J; de Vries-Idema J; van der Zee AG; Wilschut J; Daemen T
    Vaccine; 2008 May; 26(19):2314-21. PubMed ID: 18400343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.